You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

31 Results
Drug
Other Name(s): Xgeva®; Wyost™
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB Limited Use
    denosumab (Wyost™ brand) - For the treatment of bony metastases for patients with hormone refractory prostate cancer as determined by an elevated PSA level, or evidence of progressive bony disease, despite castrate serum testosterone levels or having undergone orchidectomy, according to clinical criteria
New Drug Funding Program
    Denosumab (Biosimilar) - Hormone Refractory Prostate Cancer
Sep 2024
Regimen
Cancer Type:
Breast, 
Genitourinary, 
Renal cell / Kidney, 
Lung, 
Non-Small Cell, 
Small Cell, 
Unknown Primary
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Sarcoma, 
Giant Cell Tumour
Intent: Curative
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Jun 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Exceptional Access Program
    pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria
Feb 2024
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2024
Regimen
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024

Pages